Published October 20, 2026 4:57pm EDT

The recall affects 23 vials of prescription injections and follows an earlier FDA warning about the company's sterile drug production practices.

Apothecary Pharma is recalling 23 vials of injectable drugs distributed nationwide because their sterility cannot be assured, according to the Food and Drug Administration.

The voluntary recall includes 22 vials of compounded tirzepatide, a GLP-1 medication containing the same active ingredient as Eli Lilly's Mounjaro and Zepbound, and one vial of NAD+ injection. The FDA classified the recall as Class II on Oct.…